

TETRAHEDRON

Synthesis of Didemnolines A-D, N9-Substituted β -Carboline Alkaloids from the Marine Ascidian *Didemnum* sp.

Robert W. Schumacher[†] and Bradley S. Davidson*[‡]

[†]Department of Chemistry and Biochemistry, Utah State University, Logan, Utah 84322-0300 and [†]Department of Chemistry, University of Hawaii at Manoa, Honolulu, Hawaii 96822

Received 21 October 1998; revised 12 November 1998; accepted 20 November 1998

Abstract: Didemnolines A-D (1-4) were synthesized and their structures were confirmed through comparisons of data for the synthetic material with those obtained for natural 1-4. The synthesis of didemnolines A (1) and C (3) involved the coupling of 1-[(benzyloxy)methyl]-4-chloromethyl-5-(thiomethyl)imidazole (6) with 7-bromo- β -carboline (5), while didemnolines B (2) and D (4) were formed through the analogous coupling of 6 with norharmon (7). Intermediate 6 was efficiently prepared from 1-[(benzyloxy)methyl]-2,4,5-tribromoimidazole using a sequential one-pot halogen-metal exchange reaction and 7-Br- β -carboline was synthesized using a new approach. © 1999 Elsevier Science Ltd. All rights reserved. Keywords: Natural Products, Alkaloids, Imidazoles,

Marine ascidians have gained recognition in recent years as excellent sources of a wide variety of novel amino acid-derived natural products,¹ many of which have been the focus of further biological studies as well as targets for synthetic chemists. In addition to cyclic peptides, ascidians have yielded many heteroaromatic alkaloids, including pyridoacridines² and β -carbolines.¹ Although ascidians of the genus *Eudistoma* (family Polycitoridae) have been the most common source of biologically active β -carboline derivatives,^{3,4,5} several tetrahydro- β -carboline alkaloids, e.g., lissoclin C⁶ and bengacarboline,⁷ have been isolated from ascidians belonging to the genera *Lissoclinum* and *Didemnum*, respectively, both members of the family Didemnidae.



In 1995, we reported the structures of didemnolines A-D (1-4), new β -carboline alkaloids isolated from an ascidian of the genus *Didemnum*, collected near the island of Rota, Northern Mariana Islands.⁸ The didemnolines are unusual in that their β -carboline rings are substituted at the N-9 position, rather than at the more common C-1 point of attachment. In addition, didemnolines A (1) and C (3) were biologically active, with 3 being roughly an order of magnitude more cytotoxic to KB cells (IC₅₀ values of 0.28 µg/mL for 3 versus 6.1 µg/mL for 1) and 1 being slightly more antimicrobial toward *Staphylococcus aureus*, *Bacillus subtilis*, and *Escherichia coli*. In order to confirm our proposed structures and allow us to ascertain the structures of several additional didemnolines, we undertook the synthesis of didemnolines A-D. We now report the results of these synthetic efforts.

Because we previously demonstrated that didemnoline C (3) could be generated from didemnoline A (1) by treatment with NaIO₄,⁸ our retrosynthetic analysis (see Scheme 1) involved the straightforward disconnection of the N-9/C-10 bond. Therefore, compounds 1 and 3 could be formed through the coupling of 7-bromo- β -carboline (5, = eudistomin O), previously prepared by Rinehart and co-workers from 4-methyl-3-nitroaniline,^{3c}

Corresponding author. E-mail: davidson@cc.usu.edu

with an appropriately substituted imidazole moiety (6) that may be formed directly from imidazole. Similarly, didemnolines B (2) and C (4) could be formed from imidazole 6 and commercially available norharmon (7, = β -carboline).

Scheme 1. Retrosynthetic Plan.



Synthesis of Imidazole 6.

The imidazole ring system has been studied more than any of the other azole ring systems because many imidazole derivatives, e.g., histamine and nucleosides, possess biological activity. The development and refinement of synthetic methods for the functionalization of imidazole rings continues to be a central concern in the pursuit of biologically active synthetic analogs of naturally occurring imidazole-based compounds. Our approach for the formation of compound 6 involved the use of the sequential halogen-metal exchange method.⁹ Although it has been known for some time that the rate of halogen-metal exchange in 2,4,5-trihalogenated imidazoles occurs in the order C-2 > C-5 >> C-4, early reports describing this regioselectivity were filled with contradictions as to whether 4,5-dihalogenated imidazoles could be functionalized directly at the C-4 and C-5 positions, without first protecting the C-2 position. In 1991, Groziak and co-workers clearly showed that upon treatment of 2-unprotected-4,5-diiodoimidazoles with *n*-BuLi, the initially formed 5-yllithium species equilibrates to form a 2-yllithium species, which can then react with an electrophile,⁹⁴ demonstrating the need for C-2 substitution when the C-5 position is to be functionalized. Based on this finding, the authors developed a one-pot procedure for preparing 2H-4,5-disubstituted imidazoles using a transient protecting group at C-2.⁹⁷ This approach provides a method for the preparation of 2-unsubstituted-4,5-unsymmetrically disubstituted imidazoles such as 6.

Scheme 2. Synthetic Route to Imidazole 6.



The requisite N-protected, polyhalogenated imidazole was prepared in two steps by treatment of imidazole with Br_2 in dry acetic acid to give the 2,4,5-tribromoimidazole product, which was then protected at N-1 by treatment with BOMCl and K_2CO_3 in DMF, yielding compound 8 in 63% yield from imidazole. As discussed earlier, in order to functionalize the C-4 and C-5 positions, the C-2 position must be protected. Therefore, treatment of 8 with n-BuLi was followed by addition of TMSCl to afford 2-trimethylsilyl protected intermediate 9, which was not isolated but instead treated immediately with another equivalent of n-BuLi. Addition of MeSSMe yielded the intermediate 10, substituted at the C-5 position with a thiomethyl group, which was once more treated with n-BuLi. The resulting 4-yllithium species was quenched with DMF. Upon aqueous work-up, the silyl

group was hydrolyzed and chromatographic purification then gave compound 11 in 68% yield. Reduction of the aldehyde with NaBH₄, followed by treatment of the resulting alcohol with SOCl₂ provided compound 6 in 98% from 11 and in 43% overall yield from imidazole.

Synthesis of 7-Bromo- β -Carboline (5).

7-Bromo- β -carboline (5, eudistomin O) was previously synthesized by Rinehart and co-workers in 8 steps with a 7% yield.^{3c} However, because their route included several troublesome steps, we chose a modified reaction sequence, which like the Rinehart synthesis targets 6-bromoindole (12) and 1,2,3,4-tetrahydro- β -carboline (13) as intermediates (Scheme 3). Treatment of 4-bromo-2-nitrotoluene (14) with dimethylformamide dimethylacetal (DMFDMA) and pyrrolidine gave an intermediate β -pyrrolidinostyrene, which was immediately reduced with TiCl₃, yielding 6-bromoindole (12) in 77% yield.¹⁰ Compound 12 was treated with 1-dimethylamino-2nitroethylene (DMANE)¹¹ in dry TFA giving compound 15 (96%), which was reduced with NaBH₄/BF₃·OEt₂¹² to yield 6-bromotryptamine (16) in 75%. A Pictet-Spengler reaction using glyoxylic acid monohydrate¹³ then resulted in the formation of tetrahydro- β -carboline 13 in 73% yield.

Scheme 3. Synthetic Route to 7-Bromo- β -Carboline.



Oxidation of 13 to give the β -carboline ring system proved very difficult. Attempts to use diphenylselenium bis-(trifluoroacetate), as had Rinehart,^{3c} were unsuccessful. Furthermore, MnO₂, Pd/C, LiAlH₄, chloranil, and DDQ all failed to give the desired product, although each of these reagents had been reported to work in high yield when the C-1 position is substituted.¹⁴ Ultimately, dehydrogenation to give 5 was achieved using S₈ in refluxing xylene,¹⁵ albeit in only 15% yield. In terms of ease, availability of reagents, and yield, this route provides a significant improvement for the synthesis of 7-bromo- β -carboline over that previously reported by Rinehart.^{3c}

Formation of Didemnolines A (1) and B (2).

The final coupling of β -carbolines 5 and 7 with imidazole 6 to form didemnolines A (1) and B (2) was accomplished as follows (Scheme 4). Addition of 6 to a solution of 5 and powdered KOH in DMF afforded BOM-didemnoline A (17) in 68% yield. Removal of the BOM group with 6N HCl at 110 °C then provided didemnoline A (1) in 91% yield. A similar protocol using 7 instead of 5 gave didemnoline B in 65% yield over two steps, via 18. The spectral data for synthetic 1 and 2 matched closely those of natural didemnolines A and B, respectively, unambiguously confirming the proposed structures.⁸

Conversion of Didemnolines A and B to Didemnolines C and D.

As previously shown, didemnolines A and B could be used to form didemnolines C and D, respectively.⁸ Synthetic 1 was treated with NaIO₄ in MeOH/H₂O for 24 h at RT yielding a product, which, after chromatographic purification was indistinguishable from natural didemnoline C (3). Likewise, treatment of synthetic 2 with NaIO₄ provided a product yielding NMR data that matched the signals assigned to didemnoline D (4) in the original spectrum containing 3 and 4,⁸ thus confirming the proposed structure.



Summary.

Didemnolines A-D (1-4) have been synthesized. The synthesis of didemnolines A (1) and C (3) involved the coupling of 7-bromo- β -carboline (5) with 1-[(benzyloxy)methyl]-4-chloromethyl-5-(thiomethyl)imidazole (6), which was prepared in a single step from 1-[(benzyloxy)methyl]-2,4,5-tribromoimidazole using an approach involving sequential halogen-metal exchange. Although 7-bromo- β -carboline (5), also known as the natural product eudistomin $O_{,3}^{,\infty}$ had been previously synthesized, an improved route was developed. Didemnolines B (2) and D (4) were similarly prepared by coupling imidazole 6 with norharmon (7). These results have allowed the proposed structures to be confirmed, provided sufficient material for further biological testing, and have furnished a method by which the structures of four additional, and as yet unpublished, didemnolines can be confirmed. Their structures will be reported in the near future.

EXPERIMENTAL SECTION

General. Unless otherwise noted, materials and solvents were obtained from commercial suppliers and used without further purification. THF and pyrrolidine were distilled from Na/benzophenone immediately prior to use. Anhydrous solvents were added using syringes. Chromatography was carried out using silica gel (Merck 60, 60 Å, 230-400 mesh) according to the procedure described by Still.¹⁶ Reactions and chromatography fractions were monitored by TLC, using 2×5 cm aluminum-backed plates covered with a 0.20 mm layer of silica gel 60 F₂₅₄, Art. 5554 (E. Merck, Darmstadt). UV light and iodine were used to visualize TLC spots. All NMR experiments were performed on either a General Electric QE-300 or GE Omega 500 spectrometer. NMR spectra were recorded in either CDCl₃ [¹H, 7.26 ppm (residual CHCl₃); ¹³C, 77.0 ppm] or DMSO-d₆ [¹H, 2.49 ppm (residual DMSO-d₅); ¹³C, 39.0 ppm). El mass spectral data were obtained on a VG-70SE spectrometer and UV spectra were obtained on a Milton Roy spectronic 3000 diode array spectrophotometer. Melting points were determined on a Laboratory Devices Mel-Temp II apparatus and are uncorrected.

2,4,5-Tribromoimidazole: To a stirred solution of imidazole (1.36 g, 0.02 mmol) and NaOAc (20 g) in glacial HOAc (180 mL), was added a solution of Br₂ (9.6 g, 0.6 mmol) in HOAc (20 mL) over 30 min. When about one third of the bromine had been consumed, more NaOAc (5 g) was added. Stirring was continued for 2.5 h, during which time the tribromoimidazole began to precipitate. The acetic acid was evaporated and water (600 mL) was added. The white precipitate was collected, washed with water, and dried under vacuum, yielding pure 2,4,5-tribromoimidazole (3.8 g, 64%): mp 218-221 °C (lit.¹⁷ 221-222 °C); ¹H NMR (CDCl₃) δ 10.20 (1H, br s); ¹³C NMR (CDCl₃) δ 116.30, 108.61; EIMS *m/z* (rel int) 308 (28), 306 (93), 304 (100), 302 (36), 279 (52), 277 (49), 225 (44), 198 (22), 93 (26); HREIMS 301.7712 (C₃H⁷⁹Br₃N₂; Δ -2.2 mmu).

I-[(Benzyloxy)methyl]-2,4,5-tribromoimidazole (8): A solution of 2,4,5-tribromoimidazole (8 g 26 mmol) in anhydrous DMF (100 mL) was treated with excess powdered K_2CO_3 (35 g). To the vigorously stirred suspension was added dropwise benzyloxymethyl chloride (4.8 g, 31 mmol) and the reaction was stirred overnight. The reaction mixture was filtered, after which the resulting oily residue slowly crystallized yielding 10.8 g (98%) of large translucent rhomboids: IR (film) v 3249, 3017, 2932, 2857, 1494, 1456, 1419, 1360, 1317, 1253, 1200, 1098, 965, 740, 692, 654, 601 cm⁻¹; ¹H NMR (CDCl₃) δ 7.35-7.33 (m), 5.41 (s), 4.59 (s); ¹³C NMR (CDCl₃) δ 135.7, 128.2, 127.9, 127.5, 127.3, 118.8, 117.3, 105.5, 75.4, 70.8; HRFABMS (3-NBA/Gly/TFA) 422.8330 (C₁₁H₁₀Br₃N₂O, MH^{*}; Δ -3.1 mmu).

Scheme 4. Final Steps Towards Didemnolines A and C.

1-[(Benzyloxy)methyl]-5-thiomethylimidazole-4-carboxaldehyde (11): To a solution of 8 (1.5 g, 3.56 mmol) in dry THF (20 mL) was added *n*-BuLi (3.56 mmol, 1.4 mL of 2.5 M) at -78 °C. After stirring for 20 min, TMSCl (452 µL, 3.56 mmol) was added dropwise via syringe and the solution was allowed to warm to RT for 2 h. The reaction was cooled to -78 °C and another aliquot of *n*-BuLi (3.56 mmol) was added and the solution was aldeed. After stirring for another 20 min at -78 °C, MeSSMe (321 µL, 3.56 mmol) was added and the solution was allowed to warm to room temperature for 2 h with stirring. The solution was again cooled to -78 °C, stirred for 30 min, and DMF (300 µL) was added. The reaction was allowed to warm to RT and after stirring for 2 h, it was poured into a separatory funnel containing saturated aqueous NH₄Cl. The aqueous solution was extracted with EtOAc, dried (MgSO₄), and concentrated, resulting in a crude yellow oil that was chromatographed over silica gel (97:3 CH₂Cl₂:MeOH) yielding pure 11 (631 mg) in 68 % as a colorless oil: UV (EtOH) λ_{max} 252 (16,500), 209 (7,100) nm; IR (film) v 3423, 3091, 2920, 1681, 1488, 1450, 1333, 1247, 1216, 1082, 842, 789, 746, 698 cm⁻¹; ¹H NMR (CDCl₃) δ 9.94 (1H, s), 7.70 (1H, s), 7.25-7.16 (5H, m), 5.41 (2H, s), 4.43 (2H, s), 2.34 (3H, s); ¹³C NMR (CDCl₃) δ 184.6, 142.5, 140.1, 135.5, 133.1, 128.2, 127.9, 127.4, 73.0, 70.5, 19.8; EIMS *m/z* (rel int) 262 (27), 247 (49), 232 (17), 203 (17), 113 (16), 92 (57), 91 (100), 65 (55).

I-[(Benzyloxy)methyl]-4-hydroxymethyl-5-(thiomethyl)imidazole: To a solution of 11 (200 mg, 0.76 mmol) in MeOH (5 mL) was added NaBH₄ (58 mg, 1.52 mmol) at RT and the solution was stirred for 15 min until the aldehyde was consumed, as determined by TLC. The solution was poured into water and extracted with EtOAc. The extract was dried (MgSO₄) and evaporated under reduced pressure to give 201 mg (100 %) of alcohol: UV (EtOH) λ_{max} 252 (28,000), 214 (4,100) nm; IR (film) v 3380, 2910, 2857, 1643, 1488, 1451, 1376, 1210, 1082, 1002, 788, 746 cm⁻¹; ¹H NMR (CDCl₃) δ 7.79 (1H, s), 7.34-7.26 (5H, m), 5.41 (2H, s), 4.71 (2H, s), 4.59 (1H, br s), 4.48 (2H, s), 2.34 (3H, s); ¹³C NMR (CDCl₃) δ 147.4, 139.3, 136.3, 128.7, 128.3, 127.9, 121.6, 73.5, 70.5, 57.0, 21.2; EIMS *m/z* (rel int) 264 (70), 234 (34), 143 (44), 91 (100), 65 (76); HREIMS 264.0910 (C₁₃H₁₆N₂O₂S; Δ +2.3 mmu).

I-[(Benzyloxy)methyl]-5-thiomethyl-4-(chloromethyl)imidazole (6): Freshly distilled SOCl₂ (119 mg, 1.0 mmol) was added to 1-[(benzyloxy)methyl]-5-thiomethyl-4-(hydroxymethyl)imidazole (132 mg, 0.5 mmol) and the neat reaction was warmed on a steam bath with stirring for 15 min. The resulting HCl salt was washed with satd NaHCO₃, dried (MgSO₄), and concentrated, giving 138 mg (98%) of 6: UV (EtOH) λ_{max} 253 (15,600), 218 (12,500), 213 (2,800) nm; IR (film) v 3391, 1643, 1547, 1494, 1456, 1381, 1253, 1211, 1093, 1023, 746, 698 cm⁻¹; ¹H NMR (CDCl₃) δ 7.68 (1H, s), 7.31-7.22 (5H, m), 5.36 (2H, s), 4.66 (2H, s), 4.46 (2H, s), 2.34 (3H, s); ¹³C NMR (CDCl₃) δ 138.2, 135.5, 135.5, 128.4, 128.2, 127.8, 126.9, 76.6, 72.3, 33.0, 20.2; EIMS *m/z* (rel int) 284 (4), 282 (5), 126 (78), 108 (42), 106 (47), 92 (67), 91 (100), 79 (67), 77 (91), 65 (83); HREIMS 282.0535 (C₁₃H₁₅³³ClN₂OS; Δ +5.0 mmu).

6-Bromoindole (12): A solution of 4-bromo-2-nitrotoluene (1.0 g, 4.65 mmol), dimethylformamide dimethyl acetal (1.6 mL, 12 mmol), and pyrrolidine (1 mL, 12 mmol) was heated for 4 h at 100-110 °C under argon with stirring. The dark red solution of the intermediate β -pyrrolidinostyrene was allowed to cool to RT and a solution of 4 M NH₄OAc (20 mL) was added. To the stirred solution was added dropwise 20% w/v aqueous TiCl₃ (17 mL, 22.0 mmol) and the resulting gray solution was stirred for 20 min and poured into a separatory funnel containing H₂O (150 mL). It was made basic (pH 10) with 1 M NaOH and the basic solution was extracted with ether (3 × 50 mL). The combined organic phase was dried (MgSO₄) and concentrated to give a red oil which was chromatographed over silica gel using CH₂Cl₂ to give 12 as a light tan solid (0.71 g, 77%): mp 91-94 °C (lit.^{3c} 94 °C); ¹H NMR (CDCl₃) δ 8.02 (1H, br s), 7.55 (1H, d, J = 8.3 Hz), 7.50 (1H, d, J = 0.1 Hz), 7.28 (1H, dd, J = 8.3, 0.1 Hz), 7.15 (1H, dd, J = 3.2 Hz), 6.60 (1H, m); ¹³C NMR (CDCl₃) δ 136.4, 126.6, 124.8, 123.0, 121.8, 115.3, 113.9, 102.6; EIMS m/z (rel int) 197 (98), 195 (100), 116 (93), 89 (38); HREIMS 194.9696 (C₈H₆⁷⁹BrN; Δ -1.2 mmu).

3-[(E)-2-Nitroethenyl]-6-bromoindole (15): To a mixture of 6-bromoindole (200 mg, 1.03 mmol) 1-dimethylamino-2-nitroethylene (102 mg, 0.88 mmol),¹¹ was added anhydrous TFA (1 mL) and the reaction was

stirred under N₂ for 30 minutes. The reaction mixture was then poured into saturated aqueous NaHCO₃ and the solution was extracted with EtOAc (2×). The combined organic phase was dried (MgSO₄), concentrated, and chromatographed over silica gel (CH₂Cl₂) to give 15 (261 mg, 96%) as yellow crystals: UV (EtOH) λ_{max} 385 (15,900), 287 (4,900), 229 (10,100) nm; ¹H NMR (DMSO-d₆) δ 12.28 (1H, s), 8.38 (1H, d, J = 13.5 Hz), 8.25 (1H, s), 8.02 (1H, d, J = 13.5 Hz), 7.93 (1H, d, J = 8.4 Hz), 7.71 (1H, d, J = 0.1 Hz), 7.33 (1H, dd, J = 8.4, 0.1 Hz). ¹³C NMR (DMSO-d₆) δ 138.4, 136.5, 133.9, 131.8, 124.4, 123.6, 122.1, 115.8, 115.3, 108.1; EIMS *m/z* (rel int) 268 (11), 266 (10), 234 (36), 232 (40), 208 (26), 207 (100), 126 (27); HREIMS 265.9699 (C₁₀H₇⁷⁹BrN₂O₂; Δ -0.8 mmu).

6-Bromotryptamine (16): A dry 100 mL flask equipped with a septum inlet, magnetic stirring bar, and a reflux condenser was cooled to 0 °C and then charged with NaBH₄ (135 mg, 4.0 mmol) followed by sequential additions of THF (10 mL) and BF₃ OEt₂ (564 μ L, 4.4 mmol) at 0 °C. The ice bath was removed and the contents were stirred at RT for 15 min. A solution of 15 (200 mg, 0.75 mmol) in THF (2 mL) was then added dropwise into the reaction flask via syringe and the reaction mixture was heated at reflux for 2 h. After cooling to room temperature, the reaction was quenched by careful addition of ice. The mixture was acidified (1*N* HCl), and then heated at 80-85 °C for another 2 h. After cooling to RT, the acidic solution was washed with ether (2 × 15 mL), after which it was made basic with aqueous NaOH to liberate the amine. Solid NaCl was added and the product was extracted into ether (3 × 25 mL). The solution was dried (MgSO₄) and concentrated under reduced pressure to yield 6-bromotryptamine (131 mg, 73%): ¹H NMR (CDCl₃) δ 9.24 (1H, s), 7.43 (1H, s), 7.41 (1H, d, *J* = 8.6 Hz), 7.18 (1H, dd, *J* = 8.6, 0.1 Hz), 6.90 (1H, s), 2.98 (2H, t, *J* = 6.4 Hz), 2.84 (2H, t, *J* = 6.4 Hz); ¹³C NMR (CDCl₃) δ 137.4, 126.4, 123.1, 122.4, 120.1, 115.4, 114.3, 42.2, 29.1; EIMS *m/z* (rel int) 238 (16), 210 (98), 208 (100), 129 (61), 128 (33), 102 (24); HREIMS 238.0092 (C₁₀H₁₁⁷⁹BrN₂; Δ +1.4 mmu).

7-Bromo-1,2,3,4-tetrahydro- β -carboline (13): A solution of glyoxylic acid monohydrate (165 mg, 1.8 mmol) in H₂O (32 mL) was added dropwise with shaking to a solution of 16 (460 mg, 1.8 mmol) in H₂O (3 mL). A cooled solution of KOH (90 mg) in water (1.6 mL) was slowly added and the mixture was stirred for 1 h, during which time a precipitate formed. The solution was filtered and the damp yellow filter cake was collected and resuspended in H₂O (16 mL). Concentrated HCl (635 mL) was added and the solution was boiled for 30 min. Another 635 mL conc HCl was added and the solution stirred for 15 min as a dark precipitate formed. Basification to pH 10 with aqueous NaOH yielded pure 13 (307 mg, 73 %) as a tan solid: mp 180-183 °C; ¹H NMR (10% CD₃OD in CDCl₃), δ 7.36 (1H, d, J = 0.1 Hz), 7.24 (1H, d, J = 8.6 Hz), 7.10 (1H, dd, J = 8.6, 0.1 Hz), 3.81 (2H, m), 3.08 (2H, m), 2.67 (2H, m); ¹³C NMR (10% CD₃OD in CDCl₃) δ 136.5, 132.5, 126.1, 122.1, 118.8, 114.4, 113.6, 107.8, 43.3, 42.4, 21.7; HRFABMS (3-NBA/Gly/TFA) 251.0186 (C₁₁H₁₃BrN₂, MH^{*}; Δ +0.8 mmu)

7-Bromo-\beta-Carboline (5): To a solution of 13 (25-100 mg) in freshly distilled xylene (1-5 mL) was added S₈ (4 equiv.) and the resulting suspension was stirred at 128 °C for 4 h. The reaction was diluted with H₂O and extracted with EtOAc. The organic phase was concentrated and the crude material was chromatographed over silica gel (95:5, CHCl₃:MeOH) giving 5 in 5-15% yield: mp 203-204 °C; ¹H NMR (CDCl₃) δ 8.71 (1H, s), 8.25 (1H, d, J = 5.4 Hz), 7.91 (1H, d, J = 8.4 Hz), 7.88 (1H, d, J = 5.4 Hz), 7.63 (1H, d, J = 1.5 Hz), 7.30 (1H, dd, J = 8.4, 1.5 Hz); ¹H NMR (DMSO-d₆) δ 8.92 (1H, s), 8.35 (1H, d, J = 5.3 Hz), 8.20 (1H, d, J = 8.8 Hz), 8.12 (1H, d, J = 5.3 Hz), 7.77 (1H, d, J = 1.8 Hz), 7.38 (1H, dd, J = 7.7, 1.8 Hz); ¹³C NMR (DMSO-d₆) δ 242.3, 238.6, 136.1, 134.4, 126.9, 123.6, 122.2, 120.8, 119.8, 114.7, 114.57; EIMS *m/z* (rel int) 248 (96), 246 (100), 223 (40), 221 (42), 167 (50), 140 (52); HREIMS 245.9796 (C₁₁H⁷⁹BrN₂; Δ -0.3 mmu).

14-[(Benzyloxy)methyl]didemnoline A (17): To a solution of powdered KOH (17 mg, 0.3 mmol) in dry DMSO (5 mL), which had stirred for 0.5 h at RT, was added 5 (12 mg, 0.05 mmol) and the mixture was stirred for another 2 h at RT. A solution of imidazole 7 (226 mg, 0.8 mmol) in DMSO (1 mL) was added dropwise and the reaction was stirred overnight. The solution was poured into H_2O and the resulting aqueous mixture was extracted with EtOAc (3×). The combined organic phase was then dried (MgSO₄) and concentrated

to 17 (16 mg) in 65% yield: UV (EtOH) λ_{max} 357 (2,900), 343 (2,800), 297 (9,900), 289 (7,300), 244 (24,600) nm; IR (film) v 3420, 1723, 1654, 1617, 1554, 1477, 1434, 1327, 1254, 1200 cm⁻¹; ¹H NMR (DMSO-d₆) δ 9.21 (1H, s), 9.04 (1H, s), 8.38 (1H, br d, J = 4.8 Hz), 8.21 (1H, d, J = 8.4 Hz), 8.13 (2H, m), 8.00 (1H, s), 7.41 (1H, dd, J = 8.4, 1.9 Hz), 7.31-7.22 (5H, m), 5.63 (2H, s), 5.44 (2H, s), 4.44 (2H, s), 2.11 (3H, s); ¹³C NMR (DMSO-d₆) δ 142.9, 141.6, 140.8, 139.0, 137.1, 136.2, 133.7, 128.3, 127.7, 127.6, 126.9, 123.6, 122.5, 121.1, 120.8, 119.7, 114.6, 113.8, 73.7, 69.8, 48.6, 20.4; HRFABMS (3-NBA/Gly/TFA) 493.0694 (C₂₄H₂₂⁷⁹BrN₄OS, MH⁺; Δ -0.7 mmu))

14-[(Benzyloxy)methyl]didemnoline B (18): To a solution of powdered KOH (170 mg, 3.0 mmol) in dry DMSO (5 mL), which had stirred for 0.5 h, was added 6 (84 mg, 0.5 mmol) and the mixture was stirred for another 2 h at RT. A solution of imidazole 6 (226 mg, 0.8 mmol) in DMSO (1 mL) was added dropwise and the reaction was stirred overnight. The solution was poured into H₂O and the resulting aqueous mixture was extracted with EtOAc (3×). The combined organic phase was then dried (MgSO₄) and concentrated to 18 (125 mg) in 60% yield: UV (EtOH) λ_{max} 356 (3,000), 343 (25,000), 288 (7,500), 296 (10,000) nm; IR (film) v 3054, 2923, 2862, 1727, 1673, 1620, 1557, 1489, 1366, 1323, 1258, 1208, 1077 cm⁻¹; ¹H NMR (CDCl₃) δ 9.30 (1H, s), 8.45 (1H, d, J = 5.4 Hz), 8.13 (1H, d, J = 7.8 Hz), 7.99 (1H, d, J = 5.4 Hz), 7.93 (1H, d, J = 8.3 Hz), 7.64 (1H, t, J = 7.1 Hz), 7.64 (1H, s), 7.31 (1H, t, J = 7.6 Hz), 7.29-7.20 (5H, m), 5.59 (2H, s), 5.37 (2H, s), 4.45 (2H, s), 2,03 (3H, s); ¹³C NMR (CDCl₃) δ 143.4, 139.7, 136.3, 136.1, 131.1, 129.9, 129.3, 128.7, 128.3, 127.9, 122.2, 122.0, 120.9, 120.4, 114.9, 110.9, 73.6, 70.6, 40.9, 21.0; HRFABMS (3-NBA/Gly/TFA) 415.1597 (C₂₄H₂₄M₄OS, MH⁺; Δ +1.0 mmu).

Didemnoline A (1): To a solution of 17 (25 mg, 0.05 mmol) in EtOH (5 mL) was added 6N HCl (1 mL) and the solution was stirred at 110 °C for 0.5 h. The reaction was poured into saturated NaHCO₃ and extracted with EtOAc. The organic phase was then concentrated to give pure 1 (17 mg) in 91% yield: UV (EtOH) λ_{max} 240 (38,700), 290 (13,500), 344 (sh), 358 (5,000) nm; IR (film) v 3443, 1683, 1493, 1441, 1327, 1200, 1138, 1053, 963, 840, 802, 721 cm⁻¹; ¹H NMR (5% TFA-*d* in DMSO-*d*₆) δ 9.58 (1H, s), 9.06 (1H, s), 8.84 (1H, d, *J* = 6.2 Hz), 8.70 (1H, d, *J* = 6.2 Hz), 8.49 (1H, d, *J* = 8.4 Hz), 8.14 (1H, d, *J* = 1.6 Hz), 7.65 (1H, dd, *J* = 8.4, 1.6 Hz), 6.01 (2H, s), 2.30 (3H, s); ¹³C NMR (CDCl₃) δ 141.6, 139.0, 137.6, 136.3, 133.6, 127.0, 123.7, 122.6, 121.2, 119.7, 114.7, 113.8, 39.0, 19.6; HRFABMS (3-NBA/Gly/TFA) 373.0119 (C₁₆H₁₄⁷⁹BrN₄S, MH^{*}; Δ -0.9 mmu).

Didemnoline B (2): To a solution of 18 (82.8 mg, 0.2 mmol) in EtOH (7 mL) was added 6N HCl (1 mL) and the solution was stirred at 110 °C for 0.5 h. The reaction was poured into saturated NaHCO₃ and extracted with EtOAc. The organic phase was then concentrated to give pure 2 (52 mg) in 87% yield: UV (EtOH) λ_{max} 358 (4,900), 243 (sh), 290 (14,100), 283 (sh), 238 (39,800), 216 (3,300) nm; IR (film) v 3049, 1622, 1493, 1451, 1328, 1264, 1211, 1208, 1028, 815 cm⁻¹; ¹H NMR (DMSO-d₆) δ 9.14 (1H, s), 8.23 (1H, d, J = 5.4 Hz), 8.03 (1H, d, J = 7.8 Hz), 7.88 (1H, d, J = 5.4 Hz), 7.79 (1H, d, J = 8.3 Hz), 7.57 (1H, t, J = 8.1 Hz), 7.24 (1H, t, J = 7.3 Hz), 5.83 (2H, s), 2.76 (3H, s); ¹³C NMR (CDCl₃) δ 141.8, 137.2, 136.8, 136.3, 131.4, 129.5, 129.1, 127.3, 123.1, 121.9, 120.8, 120.3, 114.9, 110.6, 39.5, 20.2; HRFABMS (3-NBA/Gly/TFA) 295.1021 (C₁₆H₁₅N₄S, MH⁺; Δ +1.2 mmu).

Didemnoline C (3): To a solution of 1 (2 mg) in MeOH:H₂O (9:1, 2 mL) was added NaIO₄ (1.6 mg) at 0 °C. After stirring for 24 h at 25 °C, the solid particulate was removed by filtration and the filtrate was concentrated to give a residue that was chromatographed over and amino-bonded column (CHCl₃:MeOH, 95:5) to give 3 (1.5 mg) in 75% yield: UV (EtOH) λ_{max} 352 (4,000), 342 (sh), 288 (1,400), 243 (sh), 227 (34,000) nm; ¹H NMR (5% TFA-*d* in DMSO-*d*₆) δ 9.59 (1H, s), 8.86 (1H, d, *J* = 6.1 Hz), 8.70 (1H, d, *J* = 6.1 Hz), 8.51 (1H, d, *J* = 8.4 Hz), 8.27 (1H, d, *J* = 1.5 Hz), 8.23 (1H, s), 7.65 (1H, dd, *J* = 8.4, 1.5 Hz), 6.09 (2H, s), 2.88 (3H, s); ¹³C NMR (CDCl₃) δ 142.9, 141.7, 138.8, 136.9, 135.6, 135.4, 133.9, 126.8, 123.4, 122.3, 121.3, 119.6, 114.4, 114.1, 39.0, 38.5; HRFABMS (3-NBA/Gly/TFA) 389.0061 (C₁₆H₁₄BrN₄OS, MH⁺; Δ -2.7 mmu).

Didemnoline D (4): See procedure for synthetic didemnoline C above: UV (EtOH) λ_{max} 355 (3,400), 338 (3,400), 289 (10,200), 281 (sh), 236 (27,000) nm; IR (film) v 3423, 3046, 2923, 1731, 1673, 1619, 1557, 1593, 1446, 1327, 1266, 1208 cm⁻¹; ¹H NMR (DMSO- d_6) δ 9.08 (1H, s), 8.36 (1H, d, J = 5.1 Hz), 8.24 (1H, d, J = 7.6 Hz), 8.11 (1H, d, J = 5.1 Hz), 7.77 (1H, s), 7.73 (1H, d, J = 8.3 Hz), 7.56 (1H, t, J = 7.6 Hz), 7.26 (1H, t, J = 7.6 Hz), 6.10 (2H, s), 2.88 (3H, s); ¹³C NMR (CDCl₃) δ 140.5, 138.6, 138.0, 137.8, 136.0, 133.0, 132.9, 128.1, 127.4, 121.6, 120.6, 119.6, 114.3, 110.4, 39.2, 37.4; EIMS *m/z* (rel int) 310 (4), 293 (11), 207 (30), 169 (13), 168 (100), 141 (14), 140 (18),127 (16), 125 (25),91 (11); HREIMS 310.0919 (C₁₆H₁₄N₄OS, $\Delta - 3.1$ mmu)

ACKNOWLEDGEMENTS

This work was supported in part by the American Cancer Society, in the form of a Junior Faculty Research Award (JFRA-528) to B.S.D. Mass spectrometry was provided by the Washington University Mass Spectrometry Resource with support from the NIH National Center for Research Resources (Grant No. P41RR0954).

REFERENCES

- 1. Davidson, B. S. Chem Reviews 1993, 93, 1771.
- 2. Molinski, T. F. Chem Reviews 1993, 93, 1825.
- (a) Rinehart, K. L., Jr.; Kobayashi, J.; Harbour, G. C.; Hughes, R. G., Jr.; Mizsak, S. A.; Scahill, T. A. J. Am. Chem. Soc. 1984, 106, 1524. (b) Kobayashi, J.; Harbour, G. C.; Gilmore, J.; Rinehart, K. L., Jr. J. Am. Chem. Soc. 1984, 106, 1526. (c) Rinehart, K. L., Jr.; Kobayashi, J.; Harbour, G. C.; Gilmore, J.; Mascal, M.; Holt, T. G.; Shield, L. S.; Lafargue, F. J. Am. Chem. Soc. 1987, 109, 3378. (d) Kinzer, K. F.; Cardellina II, J. H. Tetrahedron Lett. 1987, 28, 925. (e) Lake, R. J.; Brennan, M. M.; Blunt, J. D.; Munro, M. H. G. Tetrahedron Lett. 1988, 29, 2255. (f) Blunt, J. W.; Lake, R. J.; Munro, M. H. G. Tetrahedron Lett. 1987, 28, 1825. (g) Lake, R. J.; Blunt, J. W.; Munro, M. H. G. Aust. J. Chem. 1989, 42, 1201. (h) Lake, R. J.; McCombs, J. D.; Blunt, J. W.; Munro, M. H. G.; Robinson, W. T. Tetrahedron Lett. 1988, 29, 4971.
- (a) Kobayashi, J.; Nakamura, H.; Ohizumi, Y.; Hirata, Y. Tetrahedron Lett. 1986, 27, 1191. (b) Kobayashi, J.; Cheng, J.; Ohta, T.; Nozoe, S.; Ohizumi, Y.; Sasaki, T. J. Org. Chem. 1990, 55, 3666. (c) Murata, O.; Shigemori, H.; Ishibashi, M.; Sugama, K.; Hayashi, K.; Kobayashi, J. Tetrahedron Lett. 1991, 32, 3539.
- 5. Debitus, C.; Laurent, D.; Pais, M. J. Nat. Prod. 1988, 51, 799.
- 6. Searle, P. A.; Molinski, T. F. J. Org. Chem. 1994, 59, 6600-6605.
- 7. Foderaro, T. A.; Barrows, L. R.; Lassota, P.; Ireland, C. M. J. Org. Chem. 1997, 62, 6064-6065.
- 8. Schumacher, R. W.; Davidson, B. S. Tetrahedron 1995, 51, 10125-10130.
- (a) Iddon, B. J. Chem. Soc. Perkin Trans. 1, 1983, 737. (b) Iddon, B.; Khan, N. J. Chem. Soc. Perkin Trans. 1, 1987, 1445. (c) Iddon, B. J. Chem. Soc. Perkin Trans. 1, 1987, 1453. (d) Groziak, M. P.; Wei, L. J. Org. Chem. 1991, 56, 4296. (e) Ley, R. J. Org. Chem. 1991, 56, 5739. (f) Groziak, M. P.; Wei, L. J. Org. Chem. 1992, 57, 3776. (g) Iddon, B.; Ngochindo, R. I. Heterocycles 1994, 38, 2487. (h) Iddon, B.; Petersen, A. K.; Becher, J.; Christensen, N. J. J. Chem. Soc. Perkin Trans. 1, 1995, 1475.
- 10. Ayer, W. A.; Craw, P. A.; Ma, Y.; Miao, S. Tetrahedron 1992, 48, 2919.
- 11. Severin, T.; Bruck, B. Angew. Chem. 1965, 77 3847.
- 12. Varma, R. S.; Kabalka, G. W. Synth. Commun. 1985, 15, 843.
- 13. Ho, B. T.; Walker, K. E. Org. Synth. Col. Vol. VI, 1988, 965.
- 14. Snyder, H. R.; Hansch, C. H.; Katz, L.; Parmerter, S. M.; Apaeth, E. C. J. Am. Chem. Soc. 1948, 70, 219 and references cited therein.
- 15. Still, I. W. J.; McNulty, J. Heterocycles 1989, 29, 2057.
- 16. Still, W. C.; Kahn, M.; Mitra, J. J. Org. Chem. 1978, 43, 2923.
- 17. Stenio, K. E.; Wahlberg, K.; Wahren, R. Acta Chem. Scand. 1973, 27, 2179.